Tenaya Therapeutics, Inc. (TNYA) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$42.39M*; Operating income -$44.09M; Depreciation and amortization $1.70M*.
- 2026-03-31: Basis Reported; EBITDA (m); Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$19.07M*; Operating income -$20.94M; Depreciation and amortization $1.86M*.
- 2025-06-30: Basis Reported; EBITDA -$22.00M*; Operating income -$24.08M; Depreciation and amortization $2.08M*.
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | -$42.39M* | -$44.09M | $1.70M* | $1.11M | -3818.92%* | $159.00K* | -$3.55M* | (m) | $16.60M | (m) | $0.00 |
| 2026-03-31 | Reported | (m) | (m) | (m) | (m) | -8134.22% | $11.00K | -$19.23M | (m) | $14.84M | (m) | $0.00 |
| 2025-09-30 | Reported | -$19.07M* | -$20.94M | $1.86M* | (m) | (m) | $26.00K* | -$15.60M* | (m) | $15.36M | (m) | $0.00* |
| 2025-06-30 | Reported | -$22.00M* | -$24.08M | $2.08M* | $0.00 | (m) | $142.00K* | -$15.61M* | (m) | $17.37M | (m) | $0.00 |
| 2025-03-31 | Reported | -$24.88M* | -$27.54M | $2.66M | $0.00 | (m) | $383.00K | -$23.11M | (m) | $21.08M | (m) | $0.00 |
| 2024-09-30 | Reported | -$24.61M* | -$26.71M | $2.10M* | (m) | (m) | $184.00K* | -$19.84M* | (m) | $20.35M | (m) | $0.00* |
| 2024-06-30 | Reported | -$28.70M* | -$30.82M | $2.12M* | (m) | (m) | $73.00K* | -$23.62M* | (m) | $22.65M | (m) | $0.00* |
| 2024-03-31 | Reported | -$31.61M* | -$33.76M | $2.15M | (m) | (m) | $564.00K | -$28.66M | (m) | $25.05M | (m) | $0.00 |
| 2023-09-30 | Reported | -$28.74M* | -$30.92M | $2.18M* | (m) | (m) | $8.00K* | -$23.64M* | (m) | $23.09M | (m) | $0.00* |
| 2023-06-30 | Reported | -$32.91M* | -$35.10M | $2.19M* | (m) | (m) | $208.00K* | -$26.22M* | (m) | $26.48M | (m) | $0.00* |
| 2023-03-31 | Reported | -$31.59M* | -$33.72M | $2.13M | (m) | (m) | $629.00K | -$30.29M | (m) | $25.61M | (m) | $0.00 |
| 2022-09-30 | Reported | -$29.21M* | -$31.30M | $2.09M* | (m) | (m) | $4.06M* | -$27.56M* | (m) | $23.76M | (m) | $0.00* |
| 2022-06-30 | Reported | -$27.32M* | -$28.62M | $1.30M* | (m) | (m) | $7.18M* | -$25.43M* | (m) | $20.88M | (m) | $0.00* |
| 2022-03-31 | Reported | -$30.19M* | -$31.15M | $966.00K | (m) | (m) | $8.60M | -$28.76M | (m) | $24.16M | (m) | $0.00 |
| 2021-09-30 | Reported | -$17.55M* | -$18.30M | $746.00K* | (m) | (m) | $5.01M* | -$16.66M* | (m) | $12.94M | (m) | $0.00 |
| 2021-06-30 | Reported | -$14.50M* | -$15.24M | $735.00K* | (m) | (m) | $3.24M* | -$12.02M* | (m) | $10.91M | (m) | $0.00 |
| 2021-03-31 | Reported | -$12.42M* | -$13.11M | $689.00K | (m) | (m) | $4.32M | -$15.79M | (m) | $9.59M | (m) | $0.00 |
| 2020-09-30 | Reported | -$9.82M* | -$10.45M | $631.00K* | (m) | (m) | $162.00K* | -$9.53M* | (m) | $8.48M | (m) | $0.00 |
| 2020-06-30 | Reported | (m) | -$8.87M | (m) | (m) | (m) | (m) | (m) | (m) | $6.96M | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | -$84.89M* | -$93.33M | $8.44M | (m) | (m) | $618.00K | -$68.26M | (m) | $68.61M | (m) | $0.00 |
| 2024-12-31 | Reported | -$107.48M* | -$115.95M | $8.47M | (m) | (m) | $1.02M | -$90.50M | (m) | $86.74M | (m) | $0.00 |
| 2023-12-31 | Reported | -$122.51M* | -$131.19M | $8.69M | (m) | (m) | $1.24M | -$102.07M | (m) | $98.04M | (m) | $0.00 |
| 2022-12-31 | Reported | -$119.15M* | -$125.62M | $6.47M | (m) | (m) | $20.63M | -$104.42M | (m) | $94.54M | (m) | $0.00 |
| 2021-12-31 | Reported | -$69.84M* | -$72.81M | $2.96M | (m) | (m) | $25.12M | -$60.81M | (m) | $54.39M | (m) | $0.00 |
| 2020-12-31 | Reported | -$36.43M* | -$38.91M | $2.48M | (m) | (m) | $9.76M | -$35.45M | (m) | $31.10M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |